PYY3 and obesity disorder: Infusion of PYY3–36 in people with obesity causes a 30% reduction in food intake.136 A recent phase 1 study investigating a long-acting PYY3–36 analogue demonstrates a reduction of 38–55% in food intake vs. placebo at 30 days after initiation of treatment and WL of 2.87–3.58 kg compared with placebo.137